Results 221 to 230 of about 85,877 (261)

Correction: Unraveling the Secrets Behind the Multidrug-Resistant Tuberculosis Treatment Outcome in Chronic Renal Failure Patients Requiring Hemodialysis: A Systematic Review. [PDF]

Cureus
Hernandez GN, Seffah K, Zaman MA, Awais N, Satnarine T, Haq A, Patel D, Gutlapalli SD, Ahmed A, Khan S.   +9 more
europepmc   +1 more source

2D DIGE proteomic analysis of multidrug resistant and susceptible clinical Mycobacterium tuberculosis isolates: DOI: 10.5584/jiomics.v4i1.168

, 2014
Phong Quoc Truong, Elke Hammer, Manuela Gesell Salazar, Do Thi Thu Ha, Nguyễn Lan Hương, Dang Minh Hieu, Nguyen Thanh Hoa, Phung Thi Thuy, Uwe Völker   +8 more
openalex   +1 more source

Mixed infections and heteroresistance of <i>Mycobacterium tuberculosis</i> among multidrug-resistant tuberculosis in China: a genomic epidemiology study. [PDF]

Emerg Microbes Infect
Liu Y, Zhang Y, Lu X, Wu Z, Li M, Zhang R, Lu Y, Hou R, Ji Y, Zhang Q, Jiang Q, Li J, Jiang Y, Wang Y, Yuan J, Takiff HE, Chen X, Shen X, Yang C.   +18 more
europepmc   +1 more source

Bedaquiline and linezolid regimens for multidrug-resistant tuberculosis: a systematic review and meta-analysis. [PDF]

J Bras Pneumol
Cheraghi M, Amiri M, Andarzgoo S, Zarei F, Seghatoleslami ZS, Centis R, Visca D, D'Ambrosio L, Pontali E, Nasiri MJ, Migliori GB.   +10 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Multidrug-resistant tuberculosis

Nature Reviews Disease Primers
Tuberculosis (TB) remains the foremost cause of death by an infectious disease globally. Multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB; resistance to rifampicin and isoniazid, or rifampicin alone) is a burgeoning public health challenge in several parts of the world, and especially Eastern Europe, Russia, Asia and sub-Saharan Africa.
Keertan Dheda, Fuad Mirzayev, Daniela Maria Cirillo, Zarir Udwadia, Kelly E. Dooley, Kwok-Chiu Chang, Shaheed Vally Omar, Anja Reuter, Tahlia Perumal, C. Robert Horsburgh, Megan Murray, Christoph Lange   +11 more
openaire   +4 more sources

Multidrug resistant cervical tuberculosis

American Journal of Otolaryngology, 1999
Tuberculosis (TB) remains a global health problem, with an annual incidence of 8 to 10 million cases and the death of 3 million people year1y.l Despite the continuous decline of TB in the United States since the 185Os, an increase in new TB cases was observed in 1985.
A J, Vartanian, A, Alvi
openaire   +2 more sources

Multidrug-resistant tuberculosis

Infectious Disease Clinics of North America, 2002
Multidrug-resistant TB is a growing public health problem. Although control of the multidrug-resistant TB epidemic has been achieved in New York City, strains of multidrug-resistant TB are found in nearly every state. Much of the world faces a growing problem with no immediate solution.
openaire   +2 more sources

Confronting Multidrug-Resistant Tuberculosis

New England Journal of Medicine, 2012
Microbial resistance to antituberculosis drugs has existed since the dawn of the antibiotic era.1 Multidrug-resistant (MDR) tuberculosis, defined by resistance to isoniazid and rifampin, requires treatment for up to 2 years with expensive second-line drugs that have poor side-effect profiles; success rates rarely exceed 65 to 75%.
Richard E, Chaisson, Eric L, Nuermberger
openaire   +2 more sources

Multidrug-Resistant Tuberculosis Spondylitis

Acta Clinica Belgica, 2000
We report a case of multidrug-resistant spinal tuberculosis complicated by epiduritis and paraspinal abscess in a 68-year-old black woman. Multidrug-resistant tuberculous spondylitis is still rare in Belgium. Two others cases were reported from 1992 to 1997.
Cherifi, Soraya, Guillaume, Marie-Paule, Peretz, Anne   +2 more
openaire   +2 more sources